Ted Shih Selected Research

human ERBB2 protein

1/2013

Effects of Trastuzumab Emtansine (T-DM1) on QT Interval and Safety of Pertuzumab Plus T-DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ted Shih Research Topics

Disease

3	Breast Neoplasms (Breast Cancer) 01/2013 - 11/2006
2	Disease Progression 01/2013 - 11/2006
2	Neoplasms (Cancer) 01/2013 - 11/2006
1	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 01/2020
1	Hypertension (High Blood Pressure) 11/2006
1	Pancreatic Neoplasms (Pancreatic Cancer) 11/2006
1	Proteinuria 11/2006
1	Sarcoma (Soft Tissue Sarcoma) 11/2006
1	Colorectal Neoplasms (Colorectal Cancer) 11/2006
1	Renal Cell Carcinoma (Grawitz Tumor) 11/2006
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2006
1	Hemorrhage 11/2006

Drug/Important Bio-Agent (IBA)

2	pertuzumabIBA 01/2013 - 09/2012
2	Ado-Trastuzumab EmtansineIBA 01/2013 - 09/2012
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2020
1	lenzilumabIBA 01/2020
1	ErbB Receptors (EGF Receptor)IBA 01/2013
1	human ERBB2 proteinIBA 01/2013
1	Immunoconjugates (Immunoconjugate)IBA 01/2013
1	Fluorouracil (Carac)FDA LinkGeneric 11/2006
1	Biomarkers (Surrogate Marker)IBA 11/2006
1	Monoclonal AntibodiesIBA 11/2006
1	Bevacizumab (Avastin)FDA Link 11/2006
1	Angiogenesis InhibitorsIBA 11/2006
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2006

Therapy/Procedure

1	Therapeutics 11/2006